ISAL 2023 | Evaluating long-term survival in patients with AML who discontinued azacitidine-venetoclax
Sylvain Garciaz
• 21 Mar 2023
In this video, Sylvain Garciaz, MD, Paoli-Calmettes Institute, Marseille, France, discusses the results of a multicenter study which investigated the long-term survival of patients with acute myeloid leukemia (AML) who discontinued treatment with azacitidine and venetoclax due to poor tolerance. Dr Garciaz further comments on the possibility of implementing treatment-free intervals in this patient population. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
